Latest News and Events

July 2020

Nanomerics receives pIND guidance from the US FDA for NM134

Today Nanomerics received supportive pIND guidance from the US FDA on the development of its asset - NM134.  NM134 is indicated for the treatment of an undisclosed, potentially sight threatening eye disease and is enabled by Nanomerics’ Molecular Envelope Technology (MET).  Nanomerics’ MET delivers drugs across biological barriers and significantly increases drug bioavailability.  Nanomerics’ MET is non-irritant on topical application to the eye, enables the formulation of hydrophobic drugs in aqueous media and is an ocular penetration enhancer.

January 2020

Nanomerics NM127 Intranasal Enkephalin licensed to be developed by Virpax for PTSD

Nanomerics has signed a technology license agreement withVirpax® Pharmaceuticals Inc. ("Virpax"), a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems.  Virpax has acquired exclusive global rights to use Nanomerics' NM127 and its Naltos Nasal delviery Device for the management of Post-Traumatic Stress Disorder (PTSD). The agreement expands on an earlier agreement in which Virapx acquired a license to the NM127 Nalots combination product for the treatmen of pain.

Nanomerics’ Chief Scientific Officer Prof Ijeoma Uchegbu to attend Biotech Showcase 2020 - Colocated with JP Morgan Healthcare 2020 in San Francisco on 13th - 15th January 2020

Nanomerics’ Chief Scientific Officer, Prof Ijeoma F. Uchegbu will be attending Biotech Showcase 2020 from the 13th - 15th of January 2010 at the Hilton Union Square San Francisco.  This meeting is colocated with JP Morgan Healthcare 2020 in San Francisco, USA.  If you would like to meet Prof Uchegbu between the 13th and the 15th of January 2020, please email your request for a meeting to info@nanomerics.com.  We look forward to meeting in San Francisco.  

September 2019

Meet Nanomerics at the EPM Drug Delivery and Formulation conference in Munich

Nanomerics are pleased to announce that Professor Ijeoma F. Uchegbu, Nanomerics’ Chief Scientific Officer (CSO), will be presenting on Nanomerics' award winning Molecular Envelop Technology at EPM’s Drug Delivery and Formulation Conference in Munich on the19th of September 2019. If you wish to meet with Nanomerics’ CSO in Munich, please contact us and we will arrange a meeting. 

July 2019

iPharma logo

Nanomerics’ CEO Andreas Schatzlein to presesnt key note at the 3rd Global Pharmaceutical Conference and Expo

We are delighted to announce that Nanomerics’ Chief Executive Officer (CEO), Professor Andreas Schätzlein will be presenting a paper at the iPharma 3rd Global Pharmaceutical Conference and Expo in London, UK on the 3rd and 4th July 2019.  Professor Schätzlein will discuss "The Molecular Envelope Technology (MET) Platform - Engineering for Delivery" on Thursday 4th of July 2019.  If you wish to meet with Nanomerics' CEO please get in touch.

June 2019

RSC logo

Nanomerics’ Chief Scientific Officer to present at the Royal Society of Chemistry’s Formula X meeting in Manchester, UK

We are delighted to announce that Nanomerics’ Chief Scientific Officer (CSO), Professor Ijeoma F. Uchegbu will be presenting a paper at the Royal Society of Chemistry’s Formula X conference which will take place at the University of Manchester from the 24th - 27th of June 2019.  Professor Uchegbu will be presenting a paper on the 25th of June 2019.   If you wish to meet with Nanomerics' CSO on the 25th of June, please get in touch.

May 2019

Nanomerics presenting at EPM Drug Delivery and Formulation Munich

Nanomerics are pleased to announce that Professor Ijeoma F. Uchegbu, Nanomerics’ Chief Scientific Officer (CSO), will be presenting on Nanomerics' award winning Molecular Envelop Technology at EPM’s Drug Delivery and Formulation Conference in Munich on the 20th of September 2019.  If you wish to meet with Nanomerics’ CSO in Munich, please get in touch and we will arrange a meeting.  

April 2019

February 2019

Nanomerics announces new US and Japan patents

Nanomerics is pleased to announce the imminent publication of key patents underpinning its NM127 asset. Nanomerics has been notified by the US Patent and Trademark Office of the imminent publication of US10213474 on the 26th of February.  This key patent further strengthens Nanomerics patent portfolio and enables Nanomerics to continue the development of NM127.  Nanomerics is also pleased to announce a notice of allowance issued by the Japanese Intellectual Property Office for application JP2016-526933.

Pages